The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients

Table 1

Baseline demographic and clinical characteristics of the haemodialysis population.

Parameters
Patients ()	75
Age (years)	56.6 ± 11.77
Male (%)	48 (64.9%)
Primary renal disease (%)
Diabetes	22 (28.2)
Glomerulonephritis	10 (12.8)
Unknown	24 (30.7)
Vascular	12 (15.3)
Others	10 (12.8)
Vascular access (%)
Fisulta	70 (93)
Catheter	5 (7)
Viral hepatitis B or C (%)	0
Patients on antihypertensive therapy (%)	35 (46.66)
Statins (%)	31 (41.33)
Time on dialysis (months)	75.2 ± 25.6
Predialysis systolic BP (mmHg)	138 ± 21.6
Predialysis diastolic BP (mmHg)	81 ± 2,6
Dry weight (kg)	68.2 ± 7.6
Haemoglobin (g/dL)	10.91 ± 1.56
Albumin (g/L)	3.9 ± 0.82
C-reactive protein (mg/L)	5.25 [1.9–11.6]
Ferritin (ng/mL)	392.64 ± 250
Transferrin saturation (%)	29.5 ± 5.4
	1.25 [1.06–1.57]
Dialysis session length	243.7 ± 15.6
Intact parathyroid hormone (pg/mL)	362.7 [170.9–521.2]
Calcium (mg/dL)	9.39 ± 0.71
Phosphate (mg/dL)	4.33 ± 1.83
Cholesterol (mg/dL)	166.2 ± 49.2
LDL	94.34 ± 33.2
HDL	40.79 ± 20.6
Triglyceride (mg/dL)	130.5 ± 23.6